We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunology, Neuroscience Step Up as Key Growth Engines for J&J
Read MoreHide Full Article
Key Takeaways
J&J's immunology sales fell 12% in 2025 as Stelara dropped 42% after losing exclusivity.
J&J saw Tremfya sales jump 41% to over $5B, while Simponi rose 22% to $2.7B.
J&J's neuroscience sales climbed 10%, with Spravato up 57% and Caplyta reaching $700M.
Johnson & Johnson (JNJ - Free Report) is one of the key pharmaceutical players in the oncology segment, with its Oncology segment comprising around 27% of total revenues and 42% of its Innovative Medicine segment sales. However, J&J also boasts a strong presence in the immunology space and is gradually strengthening its position in the neuroscience area. Both these segments are gradually becoming key contributors to J&J’s top-line growth outside of oncology.
While Immunology accounted for 26% of the Innovative Medicine segment sales in 2025, Neuroscience accounted for around 13%. Let's discuss each segment separately.
Immunology: J&J’s New Drugs & Candidates Offset Stelara LOE
Sales in J&J’s Immunology segment declined around 12% in 2025 due to the loss of exclusivity (“LOE”) of its multi-billion-dollar product, Stelara. Stelara sales declined around 42% in 2025. However, J&J’s other key immunology drug, Tremfya, is partially offsetting the decline. Tremfya is now the fastest-growing IL-23 therapy in the United States. Its sales rose around 41% in 2025, with global full-year sales accelerating to more than $5 billion in a year for the first time. Tremfya’s sales growth is being drivenby share gains across all indications, particularly the inflammatory bowel disease (IBD) indications and strong market growth. J&J is expecting Tremfya to exceed $10 billion in peak-year sales. Sales of another key drug, Simponi/Simponi Aria, rose around 22% to $2.7 billion.
Meanwhile, J&J also has some new products and key pipeline candidates in immunology, which can drive growth in the long term.
In 2025, it gained approval for Imaavy (nipocalimab) for treating generalized myasthenia gravis. Nipocalimab is in mid-and late-stage development for rare autoantibody-driven diseases and has the potential to create a pipeline in a product.
Regulatory applications were recently filed for another key candidate, Icotyde/icotrokinra, for moderate-to-severe plaque psoriasis with an approval expected later this year. J&J believes that Icotyde/icotrokinra has the potential to revolutionize the treatment of plaque psoriasis with a once-a-day pill. JNJ-4804 is another key candidate in its immunology pipeline, which is in mid-stage development for Crohn’s disease, ulcerative colitis and psoriatic arthritis. Both Icotyde and JNJ-4804 have blockbuster potential.
J&J’s Neuroscience Unit is Fast Picking Up?
Sales in J&J’s Neuroscience segment rose 10% in 2025, mainly driven by rising contributions from its new products like Caplyta (added from last year’s acquisition of Intra-Cellular Therapies) and Spravato.
Caplyta generated sales of $700 million in 2025. Since U.S. approval for the major depressive disorder (MDD) indication in November 2025, J&J said that Caplyta has seen its highest-ever new patient start volumes across all indications.
Spravato recorded sales of $1.7 billion in 2025, up 57% year over year,driven by strong demand trends.
Most of the drugs discussed above, Imaavy, Caplyta and Icotyde, have the potential to deliver peak sales of $5 billion.
In all, while Stelara’s loss of exclusivity has created a near-term headwind, J&J’s expanding immunology portfolio and fast-growing neuroscience franchise are helping rebalance its growth mix beyond oncology. With Tremfya gaining momentum, Spravato and Caplyta accelerating and multiple late-stage pipeline candidates with blockbuster potential, these segments are poised to play an increasingly central role in supporting the company’s long-term top-line trajectory.
Competition in the Immunology & Neuroscience Space
The companies that have significant immunology drug portfolios and pipeline are AbbVie, Eli Lilly (LLY - Free Report) , Amgen, Sanofi and Pfizer (PFE - Free Report) . In the Neurosciences space, the key companies are Biogen, Lilly and Pfizer.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Immunology, Neuroscience Step Up as Key Growth Engines for J&J
Key Takeaways
Johnson & Johnson (JNJ - Free Report) is one of the key pharmaceutical players in the oncology segment, with its Oncology segment comprising around 27% of total revenues and 42% of its Innovative Medicine segment sales. However, J&J also boasts a strong presence in the immunology space and is gradually strengthening its position in the neuroscience area. Both these segments are gradually becoming key contributors to J&J’s top-line growth outside of oncology.
While Immunology accounted for 26% of the Innovative Medicine segment sales in 2025, Neuroscience accounted for around 13%. Let's discuss each segment separately.
Immunology: J&J’s New Drugs & Candidates Offset Stelara LOE
Sales in J&J’s Immunology segment declined around 12% in 2025 due to the loss of exclusivity (“LOE”) of its multi-billion-dollar product, Stelara. Stelara sales declined around 42% in 2025. However, J&J’s other key immunology drug, Tremfya, is partially offsetting the decline. Tremfya is now the fastest-growing IL-23 therapy in the United States. Its sales rose around 41% in 2025, with global full-year sales accelerating to more than $5 billion in a year for the first time. Tremfya’s sales growth is being drivenby share gains across all indications, particularly the inflammatory bowel disease (IBD) indications and strong market growth. J&J is expecting Tremfya to exceed $10 billion in peak-year sales. Sales of another key drug, Simponi/Simponi Aria, rose around 22% to $2.7 billion.
Meanwhile, J&J also has some new products and key pipeline candidates in immunology, which can drive growth in the long term.
In 2025, it gained approval for Imaavy (nipocalimab) for treating generalized myasthenia gravis. Nipocalimab is in mid-and late-stage development for rare autoantibody-driven diseases and has the potential to create a pipeline in a product.
Regulatory applications were recently filed for another key candidate, Icotyde/icotrokinra, for moderate-to-severe plaque psoriasis with an approval expected later this year. J&J believes that Icotyde/icotrokinra has the potential to revolutionize the treatment of plaque psoriasis with a once-a-day pill. JNJ-4804 is another key candidate in its immunology pipeline, which is in mid-stage development for Crohn’s disease, ulcerative colitis and psoriatic arthritis. Both Icotyde and JNJ-4804 have blockbuster potential.
J&J’s Neuroscience Unit is Fast Picking Up?
Sales in J&J’s Neuroscience segment rose 10% in 2025, mainly driven by rising contributions from its new products like Caplyta (added from last year’s acquisition of Intra-Cellular Therapies) and Spravato.
Caplyta generated sales of $700 million in 2025. Since U.S. approval for the major depressive disorder (MDD) indication in November 2025, J&J said that Caplyta has seen its highest-ever new patient start volumes across all indications.
Spravato recorded sales of $1.7 billion in 2025, up 57% year over year,driven by strong demand trends.
Most of the drugs discussed above, Imaavy, Caplyta and Icotyde, have the potential to deliver peak sales of $5 billion.
In all, while Stelara’s loss of exclusivity has created a near-term headwind, J&J’s expanding immunology portfolio and fast-growing neuroscience franchise are helping rebalance its growth mix beyond oncology. With Tremfya gaining momentum, Spravato and Caplyta accelerating and multiple late-stage pipeline candidates with blockbuster potential, these segments are poised to play an increasingly central role in supporting the company’s long-term top-line trajectory.
Competition in the Immunology & Neuroscience Space
The companies that have significant immunology drug portfolios and pipeline are AbbVie, Eli Lilly (LLY - Free Report) , Amgen, Sanofi and Pfizer (PFE - Free Report) . In the Neurosciences space, the key companies are Biogen, Lilly and Pfizer.